Vincristine

Active pharmaceutical substance formulated in Jan Aushadhi generic products for Oncology & Critical Care treatment.

🧴 Clinical Application

CRITICAL ADMINISTRATION SAFETY MANDATE: Administer INTRAVENOUSLY ONLY. Dispense in an intravenous infusion mini-bag (50 mL 0.9% NaCl) and infuse over 5 to 10 minutes. NEVER dispense or administer vincristine in a syringe to prevent accidental intrathecal injection. Standard maximum single dose is capped at 2.0 mg to prevent catastrophic neurotoxicity.

⚠️ Side Effects

Common: Dose-limiting peripheral neurotoxicity (loss of deep tendon reflexes, finger/toe numbness, foot drop, wrist drop), severe constipation and paralytic ileus (autonomic neuropathy), alopecia. Minimal bone marrow suppression. Rare/Severe: FATAL neurotoxicity if given intrathecally, vocal cord paralysis, SIADH (hyponatremia), and severe vesicant extravasation ulceration.

🛡️ Safety Warnings

BLACK BOX FATAL WARNING: FOR INTRAVENOUS USE ONLY — FATAL IF GIVEN BY OTHER ROUTES. Intrathecal administration causes ascending encephalomyelopathy and 100% fatal destruction of the central nervous system. Cap single doses at 2 mg. Autonomic neuropathy causes severe paralytic ileus; institute prophylactic bowel regimens. Vesicant agent.